Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Inhibikase Therapeutics Inc Market Cap
The Inhibikase Therapeutics Inc (IKT) share price is expected to increase by 139.73% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered IKT. Price targets range from $5 at the low end to $8 at the high end. The current analyst consensus for IKT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Inhibikase Therapeutics Inc has a total of 3 Wall St Analyst ratings. There are 3 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Inhibikase Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of IKT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Dennis Ding Jefferies | Buy | $8 | Initiates | Nov 8, 2024 |
| Edward White HC Wainwright & Co. | Buy | $5 | Maintains | Oct 14, 2024 |
| Edward White HC Wainwright & Co. | Buy | $15 | Maintains | Aug 16, 2024 |
| Edward White HC Wainwright & Co. | Buy | $23 | Maintains | May 21, 2024 |
| Edward White HC Wainwright & Co. | Buy | $27 | Reiterates | Mar 7, 2024 |
| Edward White HC Wainwright & Co. | Buy | $27 | Maintains | Mar 5, 2024 |
| Edward White HC Wainwright & Co. | Buy | $27 | Reiterates | Aug 15, 2023 |
| Edward White HC Wainwright & Co. | Buy | $27 | Maintains | Jun 30, 2023 |
| Edward White HC Wainwright & Co. | Buy | $5 | Reiterates | Jun 22, 2023 |
| Edward White HC Wainwright & Co. | Buy | $5 | Initiates | Apr 18, 2023 |
| Soumit Roy JonesTrading | Hold | Downgrade | Nov 16, 2022 | |
| Soumit Roy JonesTrading | Buy | $12 | Initiates | Jul 15, 2021 |
When did it IPO
2020
Staff Count
8
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Milton H. Werner Ph.D.
Market Cap
$134.8M
In 2023, IKT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IKT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 19 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - The company received FDA approval for a late-stage study of IKT-001Pro for pulmonary arterial hypertension, supported by $275 million in funding. Risvodetinib is in phase 2 for Parkinson's, with data expected Q4 2024.
Why It Matters - FDA approval for IKT-001Pro boosts the company's prospects in treating pulmonary arterial hypertension, while funding and upcoming data from Risvodetinib create potential growth catalysts for investors.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IkT-001Pro advances to late-stage clinical trials for pulmonary arterial hypertension, supported by up to $275 million in transformative financing from top-tier institutional healthcare investors.
Why It Matters - The $275 million financing signals strong institutional confidence in IkT-001Pro's potential, boosting its late-stage trial prospects and potentially increasing market value.
Mon, 21 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Inhibikase Therapeutics closed a $110M private placement for developing IkT-001Pro, targeting Pulmonary Arterial Hypertension, with potential total financing of $275M.
Why It Matters - Inhibikase's development of IkT-001Pro as a potential disease-modifying treatment and the substantial $110 million financing signal strong growth prospects, crucial for investor confidence and stock performance.
Wed, 09 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Inhibikase Therapeutics has announced a $110 million private placement led by Soleus Capital to fund a Phase 2b trial in pulmonary arterial hypertension and for general corporate needs.
Why It Matters - The $275 million investment led by Soleus Capital signals strong confidence in Inhibikase's potential, while the $110 million financing will fund critical clinical trials, impacting future growth and stock value.
Thu, 15 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Inhibikase Therapeutics, Inc. (NASDAQ: IKT) will host its Q2 2024 earnings call on August 15, 2024, at 8:00 AM ET, with key executives and analysts participating.
Why It Matters - Earnings calls provide insights into a company's financial health and future prospects, influencing stock performance and investor sentiment. Key participants may indicate strategic focus areas.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Inhibikase Therapeutics reported Q2 2024 financial results, highlighting progress in its drug pipeline for Parkinson's disease treatments, including risvodetinib and IkT-001Pro.
Why It Matters - Inhibikase's financial results and pipeline progress indicate potential growth and innovation in Parkinson's disease treatments, affecting stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
